and had a near death experience; passed out; feel ill; headache; dizziness/light headedness; loss of appetite; loss of sense of smell; sleeplessness; coughing; chest pain; anxiety; palpitation; This is a spontaneous report received from a contactable reporter(s) (Other HCP) from product quality group. The reporter is the patient.  A 30 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 01May2021 (Lot number: EW0153) at the age of 30 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Past drug history included: Shellfish, reaction(s): "Allergy"; Peanut, reaction(s): "Allergy"; Cashew nut, reaction(s): "Allergy". Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: ER8736, Location of injection: Arm Left, Route of Administration: Intramuscular), administration date: 10Apr2021, when the patient was 30 years old, for COVID-19 Immunization. The following information was reported: NEAR DEATH EXPERIENCE (medically significant) with onset 26Dec2021, outcome "recovering", described as "and had a near death experience"; MALAISE (non-serious) with onset 26Dec2021, outcome "recovering", described as "feel ill"; LOSS OF CONSCIOUSNESS (non-serious) with onset 26Dec2021, outcome "recovering", described as "passed out "; HEADACHE (non-serious) with onset 26Dec2021, outcome "recovering", described as "headache"; DIZZINESS (non-serious) with onset 26Dec2021, outcome "recovering", described as "dizziness/light headedness"; DECREASED APPETITE (non-serious) with onset 26Dec2021, outcome "recovering", described as "loss of appetite"; ANOSMIA (non-serious) with onset 26Dec2021, outcome "recovering", described as "loss of sense of smell"; INSOMNIA (non-serious) with onset 26Dec2021, outcome "recovering", described as "sleeplessness"; COUGH (non-serious) with onset 26Dec2021, outcome "recovering", described as "coughing"; CHEST PAIN (non-serious) with onset 26Dec2021, outcome "recovering", described as "chest pain"; ANXIETY (non-serious) with onset 26Dec2021, outcome "recovering", described as "anxiety"; PALPITATIONS (non-serious) with onset 26Dec2021, outcome "recovering", described as "palpitation". The events "covid-19 positive", "covid-19 positive", "and had a near death experience", "feel ill", "passed out ", "headache", "dizziness/light headedness", "loss of appetite", "loss of sense of smell", "sleeplessness", "coughing", "chest pain", "anxiety" and "palpitation" were evaluated at the emergency room visit. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. There were no any other medications the patient received within 2 weeks of vaccination. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (26Dec2021) positive, notes: Nasal Swab. Therapeutic measures were taken as a result of vaccination failure, covid-19, malaise, loss of consciousness, headache, dizziness, decreased appetite, anosmia, insomnia, cough, chest pain, anxiety, palpitations.; Sender's Comments: Based on the temporal association between the events Near death experience, malaise, loss of Conscience, headache, Decreased Appetite, Anosmia, Insomnia, Cough, Anxiety, Palpitations , chest pain ,Dizziness, and the suspect drug BNT162B2 cannot be excluded  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate